par Vincent, Jean Louis 
;Clausi, Carla Maria;Bruhn, Alejandro
Editeur scientifique Ortiz-Ruiz, G.;Perafan, MA;Faist, E.;Duenas Castell, C.
Référence Sepsis, Springer Science Business Media, New York, Ed. 2, page (25-32)
Publication Publié, 2006
;Clausi, Carla Maria;Bruhn, AlejandroEditeur scientifique Ortiz-Ruiz, G.;Perafan, MA;Faist, E.;Duenas Castell, C.
Référence Sepsis, Springer Science Business Media, New York, Ed. 2, page (25-32)
Publication Publié, 2006
Partie d'ouvrage collectif
| Résumé : | Sepsis, the infl ammatory response to infection, is perhaps the most common disease encountered by the critical care physician, complicating some 30% to 40% of ICU admissions and accounting for considerable morbidity and mortality. Septic shock affects some 10% to 15% of intensive care unit patients and carries mortality rates of 50% to 60%. Recent years have seen major advances in the understanding of the pathophysiology of sepsis and, as a result, new treatments and approaches to management have become available. The search to fi nd effective therapies for sepsis, one of the most common disease processes on the intensive care unit, has been rewarded in recent years with the development and licensing of drotrecogin alfa (activated), the fi rst of the so-called immunomodulatory drugs to be shown to improve outcomes in patients with severe sepsis. This milestone in the history of sepsis research has added new impetus to the ongoing quest for strategies to help decrease the still high mortality rates associated with this condition. This chapter presents some of the recent advances in sepsis management, including corticosteroids and drotrecogin alfa (activated), before refl ecting on some of the possible interventions and drugs of the future. |
